Literature DB >> 7205903

Negro alpha-thalassaemia: genetic studies in homozygous sickle cell disease.

G R Serjeant, K P Mason, B E Serjeant.   

Abstract

Interaction with the alpha-thalassaemia phenotypes lowers the proportion of Hb S in the sickle cell trait and influences the mean cell volume and proportional Hb A2 in homozygous sickle cell (SS) disease. By assigning somewhat arbitrary values to the alpha-thalassaemia 1 and alpha-thalassaemia 2 phenotypes in these conditions, it has been possible to investigate the patterns of inheritance of alpha-thalassaemia in black populations. The results strongly support the hypothesis that the alpha-thalassaemia 1 phenotype represents homozygosity for alpha-thalassaemia 2.

Mesh:

Year:  1980        PMID: 7205903      PMCID: PMC1048570          DOI: 10.1136/jmg.17.4.281

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  3 in total

1.  Negro alpha-thalassaemia is caused by deletion of a single alpha-globin gene.

Authors:  D R Higgs; L Pressley; J M Old; D M Hunt; J B Clegg; D J Weatherall; G R Serjeant
Journal:  Lancet       Date:  1979-08-11       Impact factor: 79.321

2.  The interaction of alpha thalassaemia with SS disease.

Authors:  A Swell; D Millard; G Serjeant
Journal:  Prog Clin Biol Res       Date:  1978

3.  Alpha thalassaemia in adults with sickle-cell trait.

Authors:  M H Steinberg; J G Adams; B J Dreiling
Journal:  Br J Haematol       Date:  1975-05       Impact factor: 6.998

  3 in total
  2 in total

1.  Introduction on Coronavirus Disease (COVID-19) Pandemic: The Global Challenge.

Authors:  Nima Rezaei; Saboura Ashkevarian; Mahsa Keshavarz Fathi; Sara Hanaei; Zahra Kolahchi; Seyedeh-Sanam Ladi Seyedian; Elham Rayzan; Mojdeh Sarzaeim; Aida Vahed; Kawthar Mohamed; Sarah Momtazmanesh; Negar Moradian; Zahra Rahimi Pirkoohi; Noosha Sameeifar; Mahsa Yousefpour; Sepideh Sargoli; Saina Adiban; Aida Vahed; Niloufar Yazdanpanah; Heliya Ziaei; Amene Saghazadeh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Immune-Based Therapy for COVID-19.

Authors:  Abdolreza Esmaeilzadeh; Davood Jafari; Safa Tahmasebi; Reza Elahi; Elnaz Khosh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.